Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00333866
Registration number
NCT00333866
Ethics application status
Date submitted
2/06/2006
Date registered
6/06/2006
Date last updated
11/02/2021
Titles & IDs
Public title
Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin In Patients With Fibromyalgia.
Query!
Scientific title
A 14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.
Query!
Secondary ID [1]
0
0
A0081100
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Fibromyalgia
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - pregabalin
Treatment: Drugs - pregabalin
Treatment: Drugs - pregabalin
Treatment: Drugs - placebo
Experimental: 1 -
Experimental: 2 -
Experimental: 3 -
Placebo Comparator: 4 -
Treatment: Drugs: pregabalin
600mg/day
Treatment: Drugs: pregabalin
450mg/day
Treatment: Drugs: pregabalin
300mg/day
Treatment: Drugs: placebo
placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Mean Pain Score at Endpoint (Up to Week 14)
Query!
Assessment method [1]
0
0
Daily pain diary consists of 11-point NRS ranging from 0(no pain) to 10(worst possible pain). Participants rated their pain during past 24 hours, self-assessment done daily at awakening. Baseline=Last 7 available pain scores before taking study medication up to and including Day 1. Final weekly (endpoint) mean pain score is defined as the mean pain score from the last 7 pain diary entries in the study while the participant was on study medication.
Query!
Timepoint [1]
0
0
Baseline, Week 14
Query!
Primary outcome [2]
0
0
Patient Global Impression of Change (PGIC)
Query!
Assessment method [2]
0
0
Number of participants with categorical change in overall status. PGIC: a participant-rated instrument assessing change in participant's overall status from baseline, on a scale ranging from 1 (very much improved) to 7 (very much worse).
Query!
Timepoint [2]
0
0
Week 14
Query!
Secondary outcome [1]
0
0
Change From Baseline in Mean Sleep Quality Score at Endpoint (Up to Week 14)
Query!
Assessment method [1]
0
0
Daily quality of sleep diary consists of 11-point NRS ranging from 0(best possible sleep) to 10(worst possible sleep). Participants rated their quality of sleep during past 24 hours, self-assessment done daily upon awakening. Baseline=Last 7 available scores before taking study medication up to and including Day 1. The endpoint (up to week 14) mean quality of sleep score was based on Least Squares (LS) Means using ANCOVA, with treatment group and center in the model and the baseline mean sleep score used as the covariate. Final weekly (endpoint) mean sleep quality score is defined as the mean sleep quality score from the last 7 sleep diary entries in the study while the participant was on study medication.
Query!
Timepoint [1]
0
0
Baseline, Week 14
Query!
Secondary outcome [2]
0
0
Change From Baseline in Weekly Mean Sleep Quality Score
Query!
Assessment method [2]
0
0
Daily quality of sleep diary consists of 11-point NRS ranging from 0(best possible sleep) to 10(worst possible sleep). Participants rated their quality of sleep during past 24 hours, self-assessment done daily upon awakening. Baseline=Last 7 available scores before taking study medication up to and including Day 1. The weekly mean quality of sleep score was based on LS Means using mixed model repeated measures ANCOVA, with treatment, center, week, and treatment-by-week interaction in the model and the baseline mean sleep score used as the covariate. Weekly mean sleep quality score is defined as the mean of the last 7 daily sleep diary entries.
Query!
Timepoint [2]
0
0
Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Optimal Sleep Assessed Using MOS-SS
Query!
Assessment method [3]
0
0
Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no), as well as a 9-item overall sleep problems index. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more disturbance.
Query!
Timepoint [3]
0
0
Baseline, Week 14
Query!
Secondary outcome [4]
0
0
Change From Baseline in Medical Outcomes Study (MOS): Sub-scales at Week 14
Query!
Assessment method [4]
0
0
Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no), as well as a 9-item overall sleep problems index. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more intensity of attribute.
Query!
Timepoint [4]
0
0
Baseline, Week 14
Query!
Secondary outcome [5]
0
0
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Subscale Scores at Week 14
Query!
Assessment method [5]
0
0
FIQ: 20-item self-administered questionnaire designed to assess areas such as health status, progress, and outcomes in participants with fibromyalgia. 11 items related to physical functioning, other items assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. FIQ contains 10 sub-scales scored from 0 to 10, with higher scores indicating more impairment in the subscale attribute. Total score range from 0 to 100 with higher scores indicating more impairment.
Query!
Timepoint [5]
0
0
Baseline, Week 14
Query!
Secondary outcome [6]
0
0
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Scores at Week 14
Query!
Assessment method [6]
0
0
FIQ: 20-item self-administered questionnaire designed to assess areas such as health status, progress, and outcomes in participants with fibromyalgia. 11 items related to physical functioning, other items assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. FIQ contains 10 sub-scales scored from 0 to 10, with higher scores indicating more impairment in the subscale attribute. Total score range from 0 to 100 with higher scores indicating more impairment.
Query!
Timepoint [6]
0
0
Baseline, Week 14
Query!
Secondary outcome [7]
0
0
Change From Baseline in Short Form-36 (SF-36) Health Survey at Week 14
Query!
Assessment method [7]
0
0
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning.
Query!
Timepoint [7]
0
0
Baseline, Week 14
Query!
Secondary outcome [8]
0
0
Change From Baseline in Multidimensional Assessment of Fatigue (MAF) at Week 14
Query!
Assessment method [8]
0
0
MAF is a 16-item self-administered questionnaire that yields a Global Fatigue Index (GFI), measures 4 dimensions of fatigue: degree and severity, amount of distress it causes, its timing and degree to which fatigue interferes with activities of daily living. Only 15 items are used to calculate the GFI. GFI score range from 1 (no fatigue) to 50 (severe fatigue).
Query!
Timepoint [8]
0
0
Baseline, Week 14
Query!
Secondary outcome [9]
0
0
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) at Week 14
Query!
Assessment method [9]
0
0
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Query!
Timepoint [9]
0
0
Baseline, Week 14
Query!
Secondary outcome [10]
0
0
Change From Baseline in Pain Visual Analogue Scale (VAS) Scores at Week 14
Query!
Assessment method [10]
0
0
Pain visual analog scale (VAS): Participants assessed the severity of their pain using a 100 mm visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (worst possible pain), measurement on a scale corresponds to the magnitude of their pain.
Query!
Timepoint [10]
0
0
Baseline, Week 14
Query!
Secondary outcome [11]
0
0
Total Daily Acetaminophen Dose
Query!
Assessment method [11]
0
0
Acetaminophen (up to 4 gram/day as needed for pain relief) was an allowable concomitant medication as a rescue therapy. The total daily acetaminophen dose taken during double-blind treatment was calculated for each participant as: (total acetaminophen dose during the study) divided by (total number of study days).
Query!
Timepoint [11]
0
0
Week 14
Query!
Eligibility
Key inclusion criteria
- ACR criteria for fibromyalgia
- A score of more or equal to 40 mm on the Pain Visual Analog Scale (VAS) and a an
average score more or equal to 4 on 4 daily pain diaries
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Patients with other severe pain conditions
- Patients with severe depression
- Patients taking excluded medications
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2007
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
747
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Pfizer Investigational Site - Warrawong
Query!
Recruitment hospital [2]
0
0
Pfizer Investigational Site - Maroochydore
Query!
Recruitment hospital [3]
0
0
Pfizer Investigational Site - Clayton
Query!
Recruitment hospital [4]
0
0
Pfizer Investigational Site - Fitzroy
Query!
Recruitment postcode(s) [1]
0
0
2502 - Warrawong
Query!
Recruitment postcode(s) [2]
0
0
4558 - Maroochydore
Query!
Recruitment postcode(s) [3]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
3065 - Fitzroy
Query!
Recruitment outside Australia
Country [1]
0
0
Canada
Query!
State/province [1]
0
0
British Columbia
Query!
Country [2]
0
0
Canada
Query!
State/province [2]
0
0
Manitoba
Query!
Country [3]
0
0
Canada
Query!
State/province [3]
0
0
New Brunswick
Query!
Country [4]
0
0
Canada
Query!
State/province [4]
0
0
Newfoundland and Labrador
Query!
Country [5]
0
0
Canada
Query!
State/province [5]
0
0
Ontario
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
Quebec
Query!
Country [7]
0
0
Denmark
Query!
State/province [7]
0
0
Frederiksberg
Query!
Country [8]
0
0
Denmark
Query!
State/province [8]
0
0
Svendborg
Query!
Country [9]
0
0
France
Query!
State/province [9]
0
0
Cedex 5
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Cedex
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Clermont Ferrand Cedex 1
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Paris Cedex 04
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Saint Etienne Cedex 2
Query!
Country [14]
0
0
Germany
Query!
State/province [14]
0
0
Bad Saeckingen
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Berlin
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Bonn
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Mannheim
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Muenchen
Query!
Country [19]
0
0
India
Query!
State/province [19]
0
0
Madhya Pradesh
Query!
Country [20]
0
0
India
Query!
State/province [20]
0
0
Punjab
Query!
Country [21]
0
0
India
Query!
State/province [21]
0
0
Uttar Pradesh
Query!
Country [22]
0
0
Italy
Query!
State/province [22]
0
0
Bari
Query!
Country [23]
0
0
Italy
Query!
State/province [23]
0
0
Benevento
Query!
Country [24]
0
0
Italy
Query!
State/province [24]
0
0
Bologna
Query!
Country [25]
0
0
Italy
Query!
State/province [25]
0
0
Chieti Scalo
Query!
Country [26]
0
0
Italy
Query!
State/province [26]
0
0
Perugia
Query!
Country [27]
0
0
Italy
Query!
State/province [27]
0
0
Pisa
Query!
Country [28]
0
0
Korea, Republic of
Query!
State/province [28]
0
0
Kyeongki-do
Query!
Country [29]
0
0
Korea, Republic of
Query!
State/province [29]
0
0
Seoul
Query!
Country [30]
0
0
Mexico
Query!
State/province [30]
0
0
D. F.
Query!
Country [31]
0
0
Mexico
Query!
State/province [31]
0
0
Guanajuato
Query!
Country [32]
0
0
Mexico
Query!
State/province [32]
0
0
Nuevo Leon
Query!
Country [33]
0
0
Mexico
Query!
State/province [33]
0
0
San Luis Potosi
Query!
Country [34]
0
0
Netherlands
Query!
State/province [34]
0
0
Alkmaar
Query!
Country [35]
0
0
Netherlands
Query!
State/province [35]
0
0
Den Helder
Query!
Country [36]
0
0
Netherlands
Query!
State/province [36]
0
0
Leeuwarden
Query!
Country [37]
0
0
Netherlands
Query!
State/province [37]
0
0
Rotterdam
Query!
Country [38]
0
0
Netherlands
Query!
State/province [38]
0
0
Zwolle
Query!
Country [39]
0
0
Portugal
Query!
State/province [39]
0
0
Lisboa
Query!
Country [40]
0
0
Portugal
Query!
State/province [40]
0
0
Lisbon
Query!
Country [41]
0
0
Spain
Query!
State/province [41]
0
0
Barcelona
Query!
Country [42]
0
0
Spain
Query!
State/province [42]
0
0
Cordoba
Query!
Country [43]
0
0
Spain
Query!
State/province [43]
0
0
Guadalajara
Query!
Country [44]
0
0
Sweden
Query!
State/province [44]
0
0
Linkoping
Query!
Country [45]
0
0
Sweden
Query!
State/province [45]
0
0
Molndal
Query!
Country [46]
0
0
Sweden
Query!
State/province [46]
0
0
Orebro
Query!
Country [47]
0
0
Sweden
Query!
State/province [47]
0
0
Stockholm
Query!
Country [48]
0
0
Switzerland
Query!
State/province [48]
0
0
Lausanne
Query!
Country [49]
0
0
Switzerland
Query!
State/province [49]
0
0
Zurich
Query!
Country [50]
0
0
Switzerland
Query!
State/province [50]
0
0
Zürich
Query!
Country [51]
0
0
United Kingdom
Query!
State/province [51]
0
0
Greater Manchester
Query!
Country [52]
0
0
United Kingdom
Query!
State/province [52]
0
0
Renfrewshire
Query!
Country [53]
0
0
United Kingdom
Query!
State/province [53]
0
0
Tyne And Wear
Query!
Country [54]
0
0
United Kingdom
Query!
State/province [54]
0
0
London
Query!
Country [55]
0
0
United Kingdom
Query!
State/province [55]
0
0
Poole
Query!
Country [56]
0
0
Venezuela
Query!
State/province [56]
0
0
Distrito Capital
Query!
Country [57]
0
0
Venezuela
Query!
State/province [57]
0
0
Estado Miranda
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the
efficacy and safety of pregabalin in patients with fibromyalgia.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00333866
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00333866
Download to PDF